Press release
Pharma M&A Deals Surge to USD 82.6 Billion in Q2 2025 as Big Pharma Accelerates Acquisitions in Oncology, Rare Diseases & AI-Driven Drug Discovery
M&A Trends in Pharma, Q2 2025 Market
Introduction
The M&A Trends in Pharma - Q2 2025 Market analysis reveals a high-momentum quarter, with pharmaceutical giants aggressively acquiring biotech innovators to strengthen clinical pipelines, expand therapeutic portfolios, and accelerate time-to-market for breakthrough therapies.
Key areas driving acquisition interest include:
• Oncology (ADC, IO, CAR-T, radiopharmaceuticals)
• Rare diseases & orphan drugs
• Gene therapy & RNA therapeutics
• AI drug discovery platforms
• Immunology & autoimmune diseases
• Digital-biotech & clinical trial technology
The return of high-value deals signals Big Pharma's need to offset patent cliffs and increase long-term revenue stability.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/73663
Key Takeaways
• Total M&A Deal Value (Q2 2025): USD 82.6 Billion
• Total M&A Deal Value (Q2 2024): USD 64.2 Billion
• Year-on-Year Growth: 28.6%
• Oncology accounted for 41% of all deal value.
• Major M&A players in Q2 2025 include Pfizer, Merck, Roche, Johnson & Johnson, Novartis, AstraZeneca, Sanofi, AbbVie, GSK, and Amgen.
• Mid-size biotechs in AI drug discovery, mRNA, gene editing, and radiopharmaceuticals saw the highest acquisition multiples.
Market Story
The global pharma industry entered 2025 with renewed investment strength as companies pursue pipeline diversification and innovation-led acquisitions.
1. Oncology Dominates Q2 2025 M&A with ADC & IO Deals
Oncology contributed USD 33.8 billion, driven by:
• Antibody-Drug Conjugates (ADCs)
• Immuno-oncology combinations
• Radiopharmaceutical therapies
• Cell & gene therapy assets
ADC-related acquisitions alone exceeded USD 14.5 billion in Q2.
2. Gene Therapy & mRNA Deals Accelerate
Gene therapy and RNA therapeutics accounted for USD 12.4 billion, boosted by:
• AAV vector platforms
• Ex vivo & in vivo CRISPR therapies
• SaRNA (self-amplifying RNA) vaccines
• LNP delivery technology acquisitions
This marks a 22% increase compared to Q2 2024.
3. AI-Driven Pharmaceutical Acquisitions Surge
AI & machine-learning companies reached USD 9.1 billion in acquired value, highlighting the industry's pivot to:
• Automated drug discovery
• AI-designed proteins & biologics
• Predictive systems for clinical trials
• Digital biomarkers & precision mapping
AI acquisitions boomed as Big Pharma fast-tracks R&D productivity.
4. Rare Disease & Orphan Drug Deals Gain Investor Confidence
Rare disease biotechs accounted for USD 8.7 billion, driven by:
• High pricing models
• Smaller trial populations
• Accelerated approval pathways
• Strong reimbursement structures
Companies with gene-edited and enzyme-replacement therapies saw highest valuation premiums.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/73663/m-a-trends-in-pharma-q2-2025-market
Market Segments
By Deal Type
• Full Acquisitions
• Majority Stake Acquisitions
• Strategic Buyouts
• Licensing + Acquisition Hybrid Deals
• Platform Technology Acquisitions
By Therapeutic Area
• Oncology (largest)
• Neurology
• Rare Diseases
• Infectious Diseases
• Autoimmune Disorders
• Cardio-metabolic Diseases
By Technology Focus
• AI & Machine Learning Platforms
• Gene Therapy & Gene Editing (CRISPR, Base Editing)
• mRNA & RNA Therapeutics
• Cell Therapy & CAR-T Technologies
• Radiopharmaceutical Platforms
• Multi-omics & Precision Medicine Technologies
By Region
• North America (dominates with 68% deal share)
• Europe (21%)
• Asia-Pacific (7%, fast-growing)
• Middle East & South America (4%)
Recent Developments
• Merck acquired an ADC biotech to strengthen its oncology portfolio following Keytruda's upcoming patent expiry.
• Pfizer purchased a gene-therapy company specializing in neuromuscular disorders.
• AstraZeneca completed a multibillion-dollar acquisition of an RNA-oncology firm.
• Roche expanded its AI-powered drug discovery platform via strategic acquisitions.
• J&J acquired an immunology company with late-stage autoimmune candidates.
• Sanofi strengthened its rare-disease pipeline through enzyme-replacement therapy acquisitions.
• Novartis secured a radiopharmaceutical company for targeted cancer therapy expansion.
Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=73663
Expert Quote
"The pharma M&A landscape in Q2 2025 confirms a decisive shift toward oncology leadership, gene therapy, and AI-first drug discovery models. Big Pharma is aggressively pursuing acquisitions that offer long-term clinical and commercial durability."
-Irfan Tamboli, Business Development Executive, Exactitude Consultancy
Market Drivers
• Large pharma patent cliffs (2026-2029) driving acquisition urgency
• Strong cash reserves enabling billion-dollar dealmaking
• Accelerated regulatory pathways for oncology & rare diseases
• AI reducing cost and time of early-stage R&D
• High valuation premiums for transformative platforms
• Venture-backed biotechs seeking favorable exit routes
Forecast Outlook
Pharma M&A deal activity is expected to surpass USD 350-400 billion annually by 2027, driven by:
• ADC and IO expansion across multiple tumor types
• Next-generation gene editing (base editing, prime editing)
• Rapid adoption of AI-designed biologics
• Strong Big Pharma demand for pipeline replenishment
Regional Highlights
• United States: Largest M&A hub with strong biotech clusters (Boston, San Diego, SF Bay Area).
• Europe: Growth in rare-disease and radiopharmaceutical deals.
• China & Japan: Fastest growth in AI and mRNA acquisitions.
Government & Regulatory Initiatives
• FDA & EMA accelerated reviews for oncology and gene therapy
• Favorable tax incentives for R&D heavy acquisitions
• Data-sharing initiatives boosting AI-powered research
• Expansion of global clinical trial harmonization policies
• National biotech strategy programs in U.S., U.K., Japan & Singapore
Conclusion
The pharma M&A market in Q2 2025 is experiencing exceptional momentum, driven by oncology breakthroughs, high-value gene therapy assets, and AI-driven early-stage platforms. Companies investing in transformative, multi-modal biopharma technologies will lead next-generation therapeutic markets through 2030.
This report is also available in the following languages : Japanese (製薬業界におけるM&A動向、2025年第2四半期市場), Korean (2025년 2분기 제약 시장 M&A 동향), Chinese (2025年第二季度医药行业并购趋势市场展望), French (Tendances des fusions-acquisitions dans le secteur pharmaceutique, marché du deuxième trimestre 2025), German (M&A-Trends in der Pharmabranche, Marktprognose für das 2. Quartal 2025), and Italian (Tendenze M&A nel mercato farmaceutico, secondo trimestre 2025), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/73663
Our More Reports:
Smart Hospitals Market
https://exactitudeconsultancy.com/reports/73675/smart-hospitals-market
Wireless Healthcare Market
https://exactitudeconsultancy.com/reports/73677/wireless-healthcare-market
AI in Mental Health Market
https://exactitudeconsultancy.com/reports/73679/ai-in-mental-health-market
Behavioral Healthcare Software Market
https://exactitudeconsultancy.com/reports/73681/behavioral-healthcare-software-market
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pharma M&A Deals Surge to USD 82.6 Billion in Q2 2025 as Big Pharma Accelerates Acquisitions in Oncology, Rare Diseases & AI-Driven Drug Discovery here
News-ID: 4295354 • Views: …
More Releases from Exactitude Consultancy
Immuno-Oncology Market to Reach USD 196.4 Billion by 2030,registering a strong C …
Sub-Headline: The global Immuno-Oncology Market is projected to grow from USD 92.3 billion in 2023 to USD 196.4 billion by 2030, registering a strong CAGR of 11.5%, driven by rapid expansion of checkpoint inhibitors, CAR-T therapies, tumor microenvironment modulators, and next-generation individualized cancer vaccines.
Introduction
The Immuno-Oncology (IO) Market continues to dominate global cancer therapeutics, transforming patient outcomes through precision-driven, immune-based treatments. IO therapies-including immune checkpoint inhibitors (ICI), CAR-T cell therapy, bispecific…
Lennox-Gastaut Syndrome (LGS) Clinical Market to Hit USD 3.21 Billion by 2030
Sub-Headline: The global Lennox-Gastaut Syndrome (LGS) Clinical Market is projected to grow from USD 2.08 billion in 2023 to USD 3.21 billion by 2030, registering a CAGR of 6.4%, driven by rising diagnosis rates, introduction of novel anti-seizure medications, and increased access to precision neurology care.
Introduction
The Lennox-Gastaut Syndrome (LGS) Clinical Market is rapidly expanding as pharmaceutical companies develop innovative treatments targeting refractory epilepsy, neurodevelopmental disorders, and rare seizure syndromes. LGS…
Venture Capital Investment in Pharma Surges to USD 21.4 Billion in Q2 2025 as AI …
Sub-Headline: Venture capital funding in the pharmaceutical and biotech sector reached USD 21.4 billion in Q2 2025, up from USD 17.8 billion in Q2 2024, marking a strong 20.2% YoY growth, driven by rapid advances in AI-enabled drug discovery, mRNA platforms, cell & gene therapies, and oncology innovations.
Introduction
The Venture Capital Investment Trends in Pharma - Q2 2025 Market reveals a powerful resurgence in global biopharma funding as investors continue to…
HER2-Positive Breast Cancer (HER2+ BC) Clinical Market to Reach USD 21.46 Billio …
Sub-Headline: The global HER2-Positive Breast Cancer Clinical Market is expected to rise from USD 13.82 billion in 2023 to USD 21.46 billion by 2030, registering a CAGR of 6.5%, driven by rapid uptake of antibody-drug conjugates (ADCs), dual-targeted therapies, and AI-enabled precision oncology diagnostics.
Introduction
The HER2-Positive Breast Cancer (HER2+ BC) Clinical Market is undergoing a major transformation fueled by next-generation targeted therapies, breakthrough ADCs, biosimilar expansion, and genomic testing advancements. HER2+…
More Releases for M&A
industrials m&a,m&a project management,corporate finance mergers and acquisition …
Mergers and acquisitions (M&A) in the industrial sector refer to the process of one company acquiring another company or assets in the manufacturing, construction, and engineering industries. The industrial sector is characterized by a diverse range of businesses, including heavy machinery, aerospace, and defense, chemicals, and engineering services.
https://upworkservice.com/
China M&A advisory
E-mail:nolan@pandacuads.com
The industrial sector is characterized by a high level of consolidation, with companies looking to acquire other companies to gain access…
m&a company,m&a integration,cross border merger,m&a due diligence,m&a strategy,m …
Mergers and acquisitions (M&A) are a common way for companies to grow and diversify their business operations. The process of merging or acquiring another company can be complex and time-consuming, but when executed successfully, it can bring significant benefits to the acquiring company, such as access to new markets, technologies, and customers.
https://upworkservice.com
China M&A advisory
E-mail:nolan@pandacuads.com
When it comes to successful M&A, the key is to ensure that the two companies are a…
private equity m&a,international mergers and acquisitions,technology m&a,m&a pro …
Mergers and acquisitions (M&A) are a common strategy for companies looking to expand their operations, enter new markets, or acquire new technologies. In the M&A process, there are two main parties involved: the buyer and the seller. One type of buyer that is becoming increasingly prevalent in the M&A landscape is private equity firms.
https://upworkservice.com/
China M&A advisory
E-mail:nolan@pandacuads.com
Private equity firms are investment firms that raise capital from institutional investors and high net…
buy side m&a,global m&a,bank mergers and acquisitions,m&a advisory firms,success …
Mergers and acquisitions (M&A) are a common strategy for companies looking to expand their operations, enter new markets, or acquire new technologies. In the M&A process, there are two main parties involved: the buyer and the seller. The term "buy side" refers to the party that is acquiring the target company. In contrast, the "sell side" refers to the party that is being acquired.
https://upworkservice.com/
China M&A advisory
E-mail:nolan@pandacuads.com
The buy side M&A process…
due diligence in mergers and acquisitions,recent m&a deals 2023,m&a management,m …
Due diligence is an investigation process that companies undertake prior to a merger or acquisition (M&A) in order to assess the target company's financial and operational condition. The goal of due diligence is to identify any potential risks or opportunities that may impact the value of the acquisition and to ensure that the deal is in the best interest of the acquiring company. Due diligence is a critical step in…
m&a valuation,corporate mergers,m&a business,merger integration,sell side m&a pr …
Mergers and acquisitions (M&A) are a common strategy for companies looking to expand their operations, enter new markets, or acquire new technologies. One crucial aspect of the M&A process is the valuation of the target company. Valuation is the process of determining the fair value of a company, and it is an essential step in the M&A process because it helps companies to determine the terms of the acquisition, such…
